Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG (MOLN) is a clinical-stage biotechnology pioneer advancing DARPin therapeutics for oncology and radiopharmaceutical applications. This page provides investors and industry observers with official company announcements, clinical trial milestones, and strategic partnership updates.
Access the latest developments in MOLN's Radio-DARPin Therapy platform, Switch-DARPin candidates, and ophthalmology programs. Our curated news collection enables efficient tracking of regulatory filings, preclinical data disclosures, and financial results without promotional commentary.
Key content categories include clinical trial progress, collaborative research updates with partners like Orano Med, and technology platform innovations. All materials are sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for centralized access to Molecular Partners' verified announcements. For comprehensive analysis of MOLN stock performance, visit Stock Titan's dedicated market data section.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has partnered with Novartis, granting global rights to ensovibep, an antiviral treatment for COVID-19. Novartis will lead its development and commercialization. The agreement includes a CHF 150 million milestone payment to Molecular Partners and a 22% royalty on sales in relevant territories. This collaboration aims to accelerate ensovibep's availability via expedited regulatory processes. The company's cash reserves are projected to last into 2025, strengthened by this agreement.
BVF Partners L.P. has acquired shares from Essex Woodlands Health Ventures Funds, increasing its stake in Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) to 12.21%. The transaction, effective January 10, 2022, saw Essex Woodlands drop below the 3% threshold. The CEO, Patrick Amstutz, expressed gratitude for Essex's past support and optimism about the recent clinical success of their COVID-19 drug developed with Novartis. BVF's Mark Lampert highlighted the potential of their drug, ensovibep, in combatting current and future SARS-CoV-2 variants.
Molecular Partners AG announced the successful results from the EMPATHY Part A study, focusing on its DARPin antiviral therapeutic candidate, ensovibep, for treating acute COVID-19. The primary endpoint of viral load reduction was met, while the secondary endpoint showed a 78% reduction in hospitalization and ER visits across treatment arms. No deaths occurred in patients receiving ensovibep. Upon in-licensing, Molecular Partners will receive a 150M CHF milestone payment and a 22% royalty on sales. The therapy maintains effectiveness against SARS-CoV-2 variants, including Omicron.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced that CEO Patrick Amstutz will present at key healthcare investor events in January 2022. Key conferences include the H.C. Wainwright BioConnect 2022 on January 10, the JP Morgan 40th Annual Virtual Healthcare Conference on January 12, and the Baader Helvea Swiss Equities Conference on the same day. Additionally, Amstutz will participate in the Octavian Seminar 2022 on January 14. All presentations will be available for viewing on the Molecular Partners website.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) hosted a virtual Oncology R&D Day on December 15, 2021, covering advancements in their therapeutic pipeline.
Key updates included:
- 2022 clinical strategy and corporate outlook by CEO Patrick Amstutz.
- Status of Abicipar, an anti-VEGF treatment update by COO Michael Stumpp.
- Technological advancements in DARPin therapeutics.
- Emerging treatments for AML presented by university professors.
The event highlighted continued progress despite COVID-19, including a new collaboration with Novartis.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced a collaboration with Novartis to develop DARPin-conjugated radioligand therapies (DARPin-RLTs) aimed at cancer treatment. Under the deal, Novartis will pay $20 million upfront, with potential milestone payments totaling up to $560 million and low double-digit royalties on sales. This collaboration combines Molecular Partners’ expertise in DARPin technology with Novartis’ capabilities in radioligand therapy, promising targeted delivery of radiation to tumor cells.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has confirmed that its therapeutic, ensovibep, maintains high neutralizing potency against the Omicron variant of SARS-CoV-2 in laboratory studies. This drug, part of a global Phase 2-3 study (EMPATHY) in collaboration with Novartis, has shown remarkable efficacy against prior variants as well, demonstrating an IC50 in the single-digit ng/ml range. The unique tri-specific mechanism of ensovibep is designed to effectively counter mutational burdens, promising a competitive edge against future viral variations.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a biotech firm focusing on DARPin therapeutics, announced upcoming events to showcase its oncology portfolio. Presentations will include MP0317 at ESMO Immuno-Oncology, highlighting its potential for tumor-localized immune activation, and MP0533 at ASH, aimed at acute myeloid leukemia with a unique targeting mechanism. An Oncology R&D Day is scheduled for December 15, 2021, to review the company’s strategies and candidate designs. These events aim to enhance understanding of their therapeutic approaches.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) presented promising results from its Phase 2a study of ensovibep, a treatment for mild to moderate COVID-19. All 12 patients showed reduction in viral load and achieved complete clinical symptom recovery. The drug demonstrated a favorable pharmacokinetic profile and was well tolerated without any significant adverse effects. The ongoing EMPATHY Phase 2-3 study aims to evaluate ensovibep's effectiveness in ambulatory patients, with topline data expected in early 2022, highlighting its potential against evolving variants.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced a research collaboration with experts from the University of Bern to advance its acute myeloid leukemia (AML) candidate, MP0533. This innovative candidate targets three tumor-associated antigens and engages T cells via CD3 for enhanced specificity against AML cells. Preclinical results suggest MP0533 is highly specific and potentially safe for patients, particularly older individuals. The collaboration aims to leverage advanced AML methodologies and the researchers' expertise to explore MP0533's efficacy against therapy-resistant leukemia stem cells.
FAQ
What is the current stock price of MOLECULAR PARTNERS (MOLN)?
What is the market cap of MOLECULAR PARTNERS (MOLN)?
